Navigation Links
Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
Date:12/29/2009

, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated June 27, 2008, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, our 10-K for the year ended December 31, 2008, and other recent filings. These filings are available at http://www.sec.gov . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

    For further information, contact:

     Ms. Elaine Zhao, CFO
     Tel:   +1-626-456-2789
     Email: elaine@biostarpharmaceuticals.com

     John Mattio
     HC International, Inc.
     Tel:   +1-914-669-5340 (U.S.)
     Email: john.mattio@hcinternational.net
     Web:   http://www.hcinternational.net

SOURCE Biostar Pharmaceuticals, Inc.


'/>"/>
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
3. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
4. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
5. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
6. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
7. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
8. Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 In response to ... to address sales, training and consumer engagement challenges, ... innovative mobile applications to turn their clients’ visions ... latest customized mobile app creations, are now featured ... In partnership with Toyota, StudioPMG created a robust ...
(Date:10/1/2014)... 2014 Award winning unified communications ... four new-hosted collaboration bundles that combine next generation ... conferencing experiences for low, flat rate fees. ... businesses have optimized solutions to meet their technology ... audio only minutes (1K, 5K, 10K increments) or ...
(Date:10/1/2014)... 01, 2014 TeselaGen Biotechnology ... Foundation to expand their bioCAD/CAM software suite, which uses ... DNA. The Small Business Innovation Research Phase II grant ... under exclusive license from the Lawrence Berkeley National Laboratory. ... , an LBNL laboratory that develops alternative fuel technologies ...
(Date:10/1/2014)... LONDON, Sept. 30, 2014 This ... Enzymes in US$ Million by the following ... Specialty Enzymes. Specific end-use segments also analyzed ... The report provides separate comprehensive ... Asia-Pacific, Middle East, and Latin America. Annual ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... Trial Expected to Begin in the Second Quarter ... Mpex Pharmaceuticals, Inc. today,announced that the U.S. Food ... has granted Mpex orphan drug designation for,levofloxacin solution ... to Pseudomonas aeruginosa and other bacteria in patients,with ...
... D-Pharm announced today that,it has held its Pre-IND ... the forthcoming IND submission for DP-b99, a novel ... meeting focused on the,proposed plans for the Phase ... to date, preclinical pharmacology, toxicology data,and the FDA ...
... Dramatically Improve Airway Inflammatory Disease ... Control, NEW PROVIDENCE, N.J., March 4 Aerocrine, ... (http://www.nioxmino.com ), a,hand- held point-of-care device for the measurement ... Food and Drug Administration (FDA).,Physicians in the U.S. now ...
Cached Biology Technology:Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 3D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 4
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... 1970 and 2010 populations of mammals, birds, reptiles, ... percent, says the 2014 Living Planet Report released ... loss occurs disproportionately in low-income countriesand correlates with ... In addition to the precipitous decline in wildlife ... signs about the overall health of the planet. ...
(Date:9/29/2014)... says recently identified radiation detection properties of a light-emitting ... homeland security and medical advances. , In a paper ... Optics Letters , UT Arlington Physics Professor Wei ... fabricate transparent nanoscintillators by heating nanoparticles composed of lanthanum, ... A scintillator refers to a material that glows ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... of just four factors, researchers have successfully induced ... mice to behave like embryonic stem cells. The ... publication of the journal Cell. , The cells--which ... the physical, growth, and genetic characteristics typical of ...
... by the cystic fibrosis gene has been identified by ... off the degradation system allows some proteins to regain ... aimed at curing the disease. , ... a defective gene that produces a misshapen form of ...
... Acting as a genetic Trojan horse, an experimental RNA-based drug ... into prostate cancer cells and then springs into action to ... developed at Duke University Medical Center, uses one type of ... another type, called silencing RNA, to stop the expression of ...
Cached Biology News:With few factors, adult cells take on character of embryonic stem cells 2Study reveals how cells destroy faulty proteins in cystic fibrosis 2Experimental RNA-based drug kills prostate cancer cells effectively and safely 2
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
... mutS are mismatch repair minus strains of ... repair of the newly synthesized unmethylated strand ... making them helpful in such systems as ... Systems. Both ES1301 and BMH 71-18 mutS ...
Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: